Entera Bio (NASDAQ:ENTX) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $2.89 and traded as high as $3.13. Entera Bio shares last traded at $3.06, with a volume of 203,524 shares trading hands.

Analyst Ratings Changes

Several research firms have commented on ENTX. Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. Lifesci Capital started coverage on Entera Bio in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target for the company. Guggenheim began coverage on Entera Bio in a research report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target for the company. Leerink Partners started coverage on Entera Bio in a research report on Friday, September 18th. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Entera Bio in a research note on Tuesday, September 22nd. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.60.

Entera Bio Price Performance

The stock has a 50-day simple moving average of $2.89 and a two-hundred day simple moving average of $1.89.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, equities analysts forecast that Entera Bio Ltd. will post -0.40 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Entera Bio stock. Renaissance Technologies LLC increased its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 473,442 shares of the company’s stock after purchasing an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned 0.96% of Entera Bio worth $526,000 at the end of the most recent quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.